Ibrutininb, a Bruton's Tyrokinase Inhibitor, was approved as a second line agent in recurrent Mantle cell lymphoma. The approval was based on prolongation of disease free survival only in this setting. Ibrutinib 560 mg was given in the study that led to approval.
65.8 % in Overall response rate, of which 17% were complete Response.
Warning though:
5% had bleeding (subdural Hematoma, GI bleed, or Hematuria)
Infection, myelosuppression renal toxicity abdominal pains were also part of the side effects
Change dosage (reduce) if using concomitantly a CYP3A inhibitor. Or avoid it if you can!
No comments:
Post a Comment